Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies

Allogeneic CAR Cell Therapy—More Than a Pipe Dream

(2021) Kenneth J. Caldwell et al.   Frontiers in Immunology

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells

(2021) David C Bishop et al.   BLOOD

Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer

(2021) Lauren C. Cutmore et al.   Cancers

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.

(2021) Bijal D. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).

(2021) Joseph McGuirk et al.   JOURNAL OF CLINICAL ONCOLOGY

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

(2020) S. Depil et al.   NATURE REVIEWS DRUG DISCOVERY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Value and affordability of CAR T-cell therapy in the United States

(2020) Salvatore Fiorenza et al.   BONE MARROW TRANSPLANTATION

State of the art in CAR T cell therapy for CD19+ B cell malignancies

(2020) Matthew J. Frigault et al.   JOURNAL OF CLINICAL INVESTIGATION

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

(2020) Loretta J. Nastoupil et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.

(2020) Sattva Swarup Neelapu et al.   JOURNAL OF CLINICAL ONCOLOGY

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

(2020) Michael Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges

(2020) Binod Dhakal et al.   BONE MARROW TRANSPLANTATION

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

(2020) Carlos A. Ramos et al.   JOURNAL OF CLINICAL ONCOLOGY

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

(2020) Meir Rozenbaum et al.   Frontiers in Immunology

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells

(2020) Alexandre Juillerat et al.   Frontiers in Bioengineering and Biotechnology

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

(2020) Frederick L. Locke et al.   Blood Advances

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?

(2020) Scott R. Goldsmith et al.   Frontiers in Oncology

Allogeneic CAR T cell therapies for leukemia - R1

(2019) Waseem Qasim   AMERICAN JOURNAL OF HEMATOLOGY

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

(2019) Juanjuan Zhao et al.   Journal of Hematology & Oncology

Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods

(2019) Richard P. Harrison et al.   CYTOTHERAPY

CARs of the future

(2019) Anthony F. Daniyan et al.   AMERICAN JOURNAL OF HEMATOLOGY

8CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T cells – An Off-the-Shelf, Allogeneic CAR T-Cell Immunotherapy Platform

(2019) R.R. Shen et al.   CYTOTHERAPY

CD19 CAR T cell product and disease attributes predict leukemia remission durability

(2019) Olivia C. Finney et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene editing for immune cell therapies

(2019) Stefanie R. Bailey et al.   NATURE BIOTECHNOLOGY

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy

(2019) Caron A. Jacobson et al.   BLOOD

Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable

(2019) Stacey A Cranert et al.   BLOOD

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

(2019) Chenggong Li et al.   Briefings in Functional Genomics

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation

(2019) Susan Prockop et al.   JOURNAL OF CLINICAL INVESTIGATION

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Off the shelf T cell therapies for hematologic malignancies

(2018) Bruce J. McCreedy et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Cost-effective bioprocess design for the manufacture of allogeneic CAR-T cell therapies using a decisional tool with multi-attribute decision-making analysis

(2018) Michael J. Jenkins et al.   BIOCHEMICAL ENGINEERING JOURNAL

TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma

(2018) Camille Guillerey et al.   BLOOD

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

(2018) Stefan O. Ciurea et al.   BONE MARROW TRANSPLANTATION

Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia

(2018) Franziska Blaeschke et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering

(2018) May Daher et al.   CURRENT OPINION IN IMMUNOLOGY

Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center

(2018) Fenlu Zhu et al.   CYTOTHERAPY

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

(2018) Matthew L Cooper et al.   LEUKEMIA

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects

(2018) Christos Georgiadis et al.   MOLECULAR THERAPY

Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells

(2018) Alexander S Cheung et al.   NATURE BIOTECHNOLOGY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy

(2018) Xiaojun Liu et al.   Current Research in Translational Medicine

CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment

(2018) Hasan Mollanoori et al.   HUMAN IMMUNOLOGY

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

(2018) John K. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

Reprogramming human T cell function and specificity with non-viral genome targeting

(2018) Theodore L. Roth et al.   NATURE

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

(2018) Marco Ruella et al.   NATURE MEDICINE

Universal CARs, universal T cells, and universal CAR T cells

(2018) Juanjuan Zhao et al.   Journal of Hematology & Oncology

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allogeneic CAR-T Cells: More than Ease of Access?

(2018) Charlotte Graham et al.   Cells

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

(2018) Yonghong Li et al.   Engineering

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells

(2017) Daniel T. MacLeod et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

(2017) Germán G Gornalusse et al.   NATURE BIOTECHNOLOGY

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy

(2017) Robert Zeiser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

(2017) Waseem Qasim et al.   Science Translational Medicine

A versatile system for rapid multiplex genome-edited CAR T cell generation

(2017) Jiangtao Ren et al.   Oncotarget

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

(2017) Levi J. Rupp et al.   Scientific Reports

Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation

(2017) Xiaojun Liu et al.   Protein & Cell

Matching for the nonconventional MHC-IMICAgene significantly reduces the incidence of acute and chronic GVHD

(2016) Raphael Carapito et al.   BLOOD

Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease

(2016) Paul J. Martin et al.   BLOOD

Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies

(2016) M. Sabatino et al.   BLOOD

CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

(2016) Xiaojuan Liu et al.   CELL RESEARCH

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

(2016) Claudia Zelle-Rieser et al.   Journal of Hematology & Oncology

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases

(2016) Mark J Osborn et al.   MOLECULAR THERAPY

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

(2016) Nathan Singh et al.   Science Translational Medicine

Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation

(2016) Sarah Morin-Zorman et al.   Frontiers in Immunology

Clinical manufacturing of CAR T cells: foundation of a promising therapy

(2016) Xiuyan Wang et al.   Molecular Therapy-Oncolytics

Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies

(2015) X Wang et al.   CANCER GENE THERAPY

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

(2015) Laurent Poirot et al.   CANCER RESEARCH

Potential pitfalls of CRISPR/Cas9-mediated genome editing

(2015) Rongxue Peng et al.   FEBS Journal

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy

(2015) Julien Valton et al.   MOLECULAR THERAPY

Activating and Propagating Polyclonal Gamma Delta T Cells with Broad Specificity for Malignancies

(2014) D. C. Deniger et al.   CLINICAL CANCER RESEARCH

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

(2014) B Berdien et al.   GENE THERAPY

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

(2013) C. R. Y. Cruz et al.   BLOOD

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

(2013) A. M. Leen et al.   BLOOD

Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

(2013) H. Torikai et al.   BLOOD

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

(2013) J. N. Kochenderfer et al.   BLOOD

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

(2013) Joel Crespo et al.   CURRENT OPINION IN IMMUNOLOGY

HLA Engineering of Human Pluripotent Stem Cells

(2013) Laura Riolobos et al.   MOLECULAR THERAPY

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Compact designer TALENs for efficient genome engineering

(2013) Marine Beurdeley et al.   Nature Communications

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR

(2012) H. Torikai et al.   BLOOD

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

(2012) Elena Provasi et al.   NATURE MEDICINE

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

(2011) E. Doubrovina et al.   BLOOD

Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease

(2011) Waseem Qasim et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mutation in the TCRα subunit constant gene (TRAC) leads to a human immunodeficiency disorder characterized by a lack of TCRαβ+ T cells

(2011) Neil V. Morgan et al.   JOURNAL OF CLINICAL INVESTIGATION

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

(2010) J. J. Melenhorst et al.   BLOOD

CD4+CD25+FoxP3+regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

(2009) Sylvia Feyler et al.   BRITISH JOURNAL OF HAEMATOLOGY